ASCO GU Symposium announces new findings on tumor reduction and survival outcomes in advanced renal cell carcinoma
Thomas E. Hutson, D.O., Pharm.D., Ph.D., chief of the Hematology Oncology Division in the Department of Internal Medicine at Texas Tech University Health Sciences Center (TTUHSC) and director of the ...
Metastatic bladder cancer immunotherapy outcomes better with antihistamines, study shows
Renal + Urology News highlighted research led by the University of Cincinnati's Alberto Martini, MD, that found using ...
The American Journal of Managed Care17h
Ovarian Cancer Remission Rates Remained Stable Before, After COVID-19 Pandemic
The comparable rates of remission pre- and post-pandemic suggest that COVID-19 did not negatively impact the outcomes of ...
UroToday4d
ASCO GU 2025: Final Overall Survival and New ctDNA Analysis in MET-Driven Advanced Papillary Renal Cancer (CALYPSO)
Metastatic papillary renal cancer has poor outcomes, and new treatments are needed. There is a strong rationale for investigating the combination of mesenchymal epithelial transition receptor (MET) ...
Cure Today5d
Cabometyx Combo Maintains Progression-Free Survival Benefit in Advanced RCC
Final results were consistent with previously conducted research in patients with advanced renal cell carcinoma treated with ...
UroToday6d
ASCO GU 2025: Discussant: Advancements in Urothelial Cancer Perioperative Therapy
GU ASCO annual meeting featured a urothelial carcinoma session and a discussant presentation by Dr. Scot Niglio discussing two abstracts: “Safety and efficacy of neoadjuvant immunotherapy with ...
Cure Today6d
Padcev Plus Keytruda Shows Promise for Upper Tract Urothelial Carcinoma Lesions
Results from a small retrospective analysis of patients with upper tract urothelial carcinoma lesions were shared at the 2025 ASCO Genitourinary Cancers Symposium.